Company intelligence / Profile preview

MedPark

Ownership: Private
Development stage: Other

Overview

MedPark is a leading Korean regenerative medicine company specializing in innovative biomaterials for bone grafting and musculoskeletal trauma. The company holds Korea’s first patent for bone graft material technology, has achieved global certifications including CE mark, and commercializes products such as S1 Solution Technology, COLLA, BOSS, S Derm, and S Gen. Clinical studies have been conducted in collaboration with institutions like Harvard School of Dental Medicine. Products are approved in multiple markets including Mexico[3].

Therapeutic areas: RheumatologyOther
Modalities: BiologicBiomaterialMedical device (bone grafts, regenerative scaffolds)
Industry: Implantable Medical Devices

Partnerships

Collaborations with Harvard School of Dental MedicinePartnerships with medical professionals at Seoul St. Mary’s Hospital

Beyond the preview

Go deeper on MedPark.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedPark.

Explore the full profile